What Is a GLP-1, and How Does It Actually Work?

What is GLP-1, exactly — before any drug name enters the picture

GLP-1 stands for glucagon-like peptide-1, and it's a hormone your own gut already makes, not something that only exists as an injection. Specialized cells lining your small intestine and colon, called L-cells, release it within minutes of eating — most densely in the ileum and colon, though some sit further up in the duodenum and jejunum too. It's part of a family researchers call incretin hormones, substances the gut releases specifically to help manage a meal that's already arriving.

GLP-1 doesn't work in one place. It binds a receptor found in the pancreas, the stomach, and several regions of the brain, and each site does something slightly different with the signal. That's the physiological reason a single hormone can touch appetite, digestion speed, and blood sugar all at once — it isn't three separate mechanisms, it's one signal read by three different tissues.

How does it actually curb appetite and control blood sugar?

In the pancreas, GLP-1 tells beta cells to release insulin, but only when blood sugar is already elevated — a glucose-dependent trigger, which is part of why it doesn't tend to cause the sugar crashes some older diabetes drugs did. It also dials down glucagon, the hormone that would otherwise push your liver to release more sugar into the bloodstream.

In the stomach, GLP-1 slows gastric emptying, so food sits there longer and fullness lasts longer after a meal. Researchers sometimes call this the "ileal brake" — a feedback loop where hormones released once food reaches the far end of the small intestine slow down everything happening further back. In the brain, GLP-1 receptors sit in appetite-regulating regions and turn down hunger signals directly, which is the part people usually mean when they describe "food noise" going quiet.

GLP-1 receptor agonist drugs are built to sit on that same receptor and stay active far longer than the natural hormone does, which normally breaks down within minutes. That extended activity is the entire pharmaceutical trick — same lock, a key engineered to stay in it.

Which medications are actually GLP-1 drugs? The full family map

Three molecules carry FDA approvals under seven brand names, and knowing which molecule sits behind which brand clears up most of the naming confusion:

• Semaglutide — sold as Ozempic (type 2 diabetes), Wegovy (chronic weight management, plus cardiovascular risk reduction in adults with known heart disease), and Rybelsus, the oral tablet version (type 2 diabetes).
• Tirzepatide — sold as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management, plus obstructive sleep apnea). Tirzepatide activates both the GLP-1 receptor and a second gut hormone receptor called GIP, making it a dual agonist rather than a pure GLP-1 drug — it's grouped with this class because of how it works and what it treats, not because it's a purist match.
• Liraglutide — sold as Victoza (type 2 diabetes) and Saxenda (chronic weight management). The oldest of the three molecules, with a shorter daily-injection dosing pattern rather than weekly.

If a name gets confused for a fourth family member, it's usually GLP-2 — a different hormone, from the same parent protein, that grows intestinal lining rather than touching appetite or blood sugar. GLP-1 vs. GLP-2 untangles exactly where that naming overlap comes from and why tirzepatide's GIP component doesn't put it in that other family either.

Which GLP-1 works best, or fastest, for weight loss?

There's no universal winner, but there is an honest pattern in the comparative data. Tirzepatide's dual GLP-1/GIP mechanism has produced the largest average weight loss of the three molecules in trial data, including the first true head-to-head study run against semaglutide under one protocol. Semaglutide follows behind it, still well ahead of older options, and liraglutide — the earliest and lowest-dose molecule of the group — trails both by a meaningful margin.

None of that settles which drug is right for one specific person. "Fastest" and "strongest on average" aren't the same as "best for you" once cost, insurance formulary, GI tolerance, and how long a safety track record you want are added to the decision. Rather than re-deriving those percentages here, the molecule-specific pages carry the full trial numbers and current pricing: tirzepatide's mechanism and comparative results, GLP-1 dosing schedules side by side, and real patient reviews across the whole class.

What does GLP-1 even stand for, and why does everyone just say "a GLP-1" now?

GLP-1 is short for glucagon-like peptide-1 — a name that describes its chemistry (it resembles glucagon structurally) rather than what it does. Almost nobody outside a lab says the full name out loud, which is exactly how "a GLP-1" became shorthand for the entire drug class, the way "a statin" stands in for the whole cholesterol-drug family rather than one specific pill. The shorthand works because every drug in the group, semaglutide, tirzepatide, liraglutide, shares that same GLP-1 receptor target, even though tirzepatide reaches a second receptor too.

What are the real benefits beyond weight loss?

Weight loss gets the headlines, but several of these drugs carry approvals and trial evidence that have nothing to do with the scale directly:

• Blood sugar control — the original, and still primary, use for Ozempic, Mounjaro, Victoza, and Rybelsus in type 2 diabetes.
• Cardiovascular risk reduction — Wegovy earned an FDA approval in March 2024 to reduce cardiovascular risk in adults with known heart disease and excess weight, based on the SELECT trial.
• Kidney protection — Ozempic became the first GLP-1 drug approved, in January 2025, to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, based on the FLOW trial.
• Obstructive sleep apnea — Zepbound became the first prescription medicine FDA-approved specifically for moderate-to-severe obstructive sleep apnea in adults with obesity, in December 2024, a benefit tied to tirzepatide's added GIP activity rather than a class-wide effect.

Those approvals sit with specific molecules and specific brands, not the class as a whole — Mounjaro doesn't carry Zepbound's sleep apnea label, and Ozempic's kidney indication hasn't (yet) extended to Wegovy or the other molecules.

Who shouldn't take a GLP-1?

The class carries a boxed warning — the FDA's strongest label warning — against use in anyone with a personal or family history of medullary thyroid carcinoma, or with multiple endocrine neoplasia syndrome type 2 (MEN 2). That warning traces back to thyroid tumors seen in rodent studies at doses relevant to these drugs; there isn't convincing human evidence linking GLP-1 drugs to that same thyroid cancer, but the contraindication stands regardless of that human-data gap.

• A personal or family history of medullary thyroid carcinoma, or MEN 2 syndrome.
• A history of pancreatitis — listed as a precaution across the class, since these drugs can raise that risk.
• Pregnancy, or actively trying to conceive — these drugs are generally stopped well before conception.
• Type 1 diabetes or a history of diabetic ketoacidosis, since these drugs aren't built or approved for that population.
• Severe, pre-existing gastrointestinal disease, since slowing digestion further can worsen certain conditions.

None of that is a reason to self-screen out based on a vague worry — it's a specific, narrow list a prescriber checks against your actual history before writing anything.

Where does this fit for perimenopause, specifically?

The hormone and the drugs work identically at 28 or at 52 — receptor biology doesn't shift by reproductive stage. What changes is the body responding to them. Falling, fluctuating estrogen in perimenopause tends to redirect fat storage toward the abdomen and blunt insulin sensitivity, on top of a resting metabolism already sliding from age-related muscle loss — a combination that can push a woman over a BMI or blood-sugar threshold for the first time in midlife, independent of anything she's doing differently than before.

What does a GLP-1 cost, and where do you read real reviews before choosing one?

Once the family map and the mechanism make sense, cost and legitimacy are usually the next real questions — and they vary enormously depending on molecule, brand versus compounded, and insurance.